\-\ Texto\\:\\ \ \(0\)\
\-\ mild\\ left\\ buccal\\ swelling\\.\\ there\\ is\\ a\\ 20\\ x\\ 8\\ mm\\ region\\ of\\ exposed\\ bone\\ and\\ necrotic\\ tissue\\ at\\ the\\ crest\\ of\\ the\\ posterior\\ mandibular\\ ridge\\ on\\ the\\ left\\.\ \(0\)\
\-\ debridement\\ of\\ necrotic\\ bone\\ with\\ plate\\ reconstruction\\.\ \(0\)\
\-\ \\â\\€\\¢\\ permeative\\ lytic\\ destruction\\ in\\ the\\ posterior\\ body\\ and\\ angle\\ of\\ the\\ left\\ mandible\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ associated\\ pathologic\\ fracture\\ at\\ the\\ angle\\ of\\ the\\ left\\ mandible\\ showing\\ 3\\ mm\\ lateral\\ displacement\\ and\\ foreshortening\\.\ \(0\)\
\-\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\ \(1\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\ \(0\)\
\-\ \\â\\€\\¢\\ osteoradionecrosis\ \(0\)\
\-\ \\â\\€\\¢\\ primary\\ bone\\ neoplasm\ \(0\)\
\-\ 79\\ y\\.o\\.\\ woman\\ reported\\ drainage\\ around\\ mobile\\ teeth\\ 18\\ and\\ 19\\.\\ antibiotics\\ were\\ initiated\\,\\ and\\ these\\ teeth\\ were\\ easily\\ extracted\\ by\\ her\\ dentist\\.\\ after\\ debridement\\ of\\ associated\\ chronic\\ periodontal\\ disease\\,\\ the\\ underlying\\ bone\\ was\\ noted\\ to\\ be\\ highly\\ abnormal\\ in\\ appearance\\.\\ the\\ patient\\ has\\ a\\ past\\ medical\\ history\\ of\\ crohn\\â\\€\\™s\\ disease\\ necessitating\\ colectomy\\,\\ and\\ she\\ has\\ been\\ on\\ steroid\\ medications\\ for\\ most\\ of\\ her\\ life\\.\\ she\\ also\\ carries\\ a\\ diagnosis\\ of\\ osteoporosis\\ and\\ was\\ started\\ on\\ oral\\ bisphosphonate\\ \\(ibandronate\\)\\ therapy\\ several\\ years\\ ago\ \(0\)\
\-\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\\ \\(bronj\\)\\ is\\ an\\ uncommon\\ complication\\ of\\ long\\-term\\ bisphosphonate\\ therapy\\ for\\ osteoporosis\\.\\ the\\ majority\\ \\(\\>90\\%\\)\\ of\\ reported\\ cases\\ of\\ bronj\\ have\\ been\\ in\\ patients\\ receiving\\ bisphosphonate\\ therapy\\ for\\ malignancy\\ \\(watts\\ and\\ diab\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ predisposing\\ factors\\ to\\ the\\ development\\ of\\ bronj\\ include\\ dose\\ and\\ duration\\ of\\ bisphosphonate\\ therapy\\,\\ age\\,\\ corticosteroid\\ therapy\\,\\ immune\\ compromise\\,\\ periodontal\\ disease\\,\\ surgery\\,\\ and\\ trauma\\ \\(chaturvedi\\ et\\ al\\.\\,\\ 2010\\;\\ khan\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ a\\ mouse\\ model\\ for\\ studying\\ bronj\\-like\\ disease\\ uses\\ an\\ amino\\-bisphosphonate\\ and\\ methotrexate\\ to\\ induce\\ the\\ changes\\ characteristic\\ of\\ bronj\\.\\ these\\ changes\\ are\\ associated\\ with\\ alterations\\ in\\ the\\ activity\\ of\\ specific\\ t\\ cell\\ subsets\\ \\(kikuiri\\ et\\ al\\.\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ scintigraphic\\ studies\\ demonstrate\\ that\\ bisphosphonates\\ significantly\\ decrease\\ bone\\ turnover\\ in\\ the\\ mandible\\ which\\ may\\ contribute\\ to\\ the\\ pathophysiology\\ of\\ bronj\\ as\\ well\\ \\(van\\ den\\ wyngaert\\ et\\ al\\.\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ the\\ diagnosis\\ of\\ bronj\\ is\\ made\\ clinically\\ after\\ local\\ malignancy\\ is\\ excluded\\ \\(khan\\,\\ 2010\\)\\.\\ \ \(0\)\
\-\ references\\:\\ \ \(0\)\
\-\ chaturvedi\\ p\\,\\ pai\\ ps\\,\\ chaukar\\ da\\,\\ gupta\\ s\\,\\ d\\'cruz\\ ak\\.\\ bisphosphonate\\ induced\\ osteonecrosis\\ of\\ the\\ jaw\\ masquerading\\ as\\ tumor\\:\\ a\\ word\\ of\\ caution\\ for\\ oral\\ surgeons\\ and\\ oncologists\\.\\ eur\\ j\\ surg\\ oncol\\.\\ 2010\\ jan\\ 11\\.\\ \\[epub\\ ahead\\ of\\ print\\]\\ pubmed\\ pmid\\:\\ 20071132\\.\ \(0\)\
\-\ khan\\ a\\.\\ osteonecrosis\\ of\\ the\\ jaw\\ and\\ bisphosphonates\\.\\ bmj\\.\\ 2010\\ feb\\ 2\\;340\\:c246\\.\\ doi\\:\\ 10\\.1136\\/bmj\\.c246\\.\\ pubmed\\ pmid\\:\\ 20124367\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ kikuiri\\ t\\,\\ kim\\ i\\,\\ yamaza\\ t\\,\\ akiyama\\ k\\,\\ zhang\\ q\\,\\ li\\ y\\,\\ chen\\ c\\,\\ chen\\ w\\,\\ wang\\ s\\,\\ le\\ ad\\,\\ shi\\ s\\.\\ cell\\-based\\ immunotherapy\\ with\\ mesenchymal\\ stem\\ cells\\ cures\\ bisphosphonate\\-related\\ osteonecrosis\\ of\\ the\\ jaw\\-like\\ disease\\ in\\ mice\\.\\ j\\ bone\\ miner\\ res\\.\\ 2010\\ jan\\ 29\\.\\ \\[epub\\ ahead\\ of\\ print\\]\\ pubmed\\ pmid\\:\\ 20200952\\.\ \(0\)\
\-\ van\\ den\\ wyngaert\\ t\\,\\ huizing\\ mt\\,\\ fossion\\ e\\,\\ vermorken\\ jb\\.\\ scintigraphic\\ evaluation\\ of\\ mandibular\\ bone\\ turnover\\ in\\ patients\\ with\\ solid\\ tumors\\ receiving\\ zoledronic\\ acid\\.\\ oral\\ oncol\\.\\ 2010\\ mar\\;46\\(3\\)\\:214\\-8\\.\\ epub\\ 2010\\ feb\\ 6\\.\\ pubmed\\ pmid\\:\\ 20138570\\.\ \(0\)\
\-\ watts\\ nb\\,\\ diab\\ dl\\.\\ long\\-term\\ use\\ of\\ bisphosphosphonates\\ in\\ osteoporosis\\.\\ j\\.\\ clin\\ endocrinol\\ metab\\.\\ 2010\\ feb\\ 19\\.\\ \\[epub\\ ahead\\ of\\ print\\]\\ pubmed\\ pmid\\:\\ 20173017\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ 2010\\:\\ 0\\.10578315798700674\ \(0\)\
\-\ bronj\\:\\ 0\\.08815518423966498\ \(0\)\
\-\ bisphosphonate\\:\\ 0\\.060050670929436646\ \(0\)\
\-\ bisphosphonate\\-related\\:\\ 0\\.058770122826443325\ \(0\)\
\-\ pubmed\\:\\ 0\\.05515244872191898\ \(0\)\
\-\ osteonecrosis\\:\\ 0\\.052601703624770846\ \(0\)\
\-\ epub\\:\\ 0\\.045797388499407905\ \(0\)\
\-\ jaw\\:\\ 0\\.04540185494983353\ \(0\)\
\-\ pmid\\:\\ 0\\.04484609349567793\ \(0\)\
\-\ khan\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ ahead\\:\\ 0\\.038584530676491945\ \(0\)\
\-\ print\\:\\ 0\\.03165305887089249\ \(0\)\
\-\ al\\.\\:\\ 0\\.03053734111432144\ \(0\)\
\-\ watts\\:\\ 0\\.029385061413221662\ \(0\)\
\-\ diab\\:\\ 0\\.029385061413221662\ \(0\)\
\-\ chaturvedi\\:\\ 0\\.029385061413221662\ \(0\)\
\-\ kikuiri\\:\\ 0\\.029385061413221662\ \(0\)\
\-\ wyngaert\\:\\ 0\\.029385061413221662\ \(0\)\
\-\ feb\\:\\ 0\\.028400121040186743\ \(0\)\
\-\ den\\:\\ 0\\.027074570811355177\ \(0\)\
\-\ t\\:\\ 0\\.026371373464032174\ \(0\)\
\-\ osteoporosis\\:\\ 0\\.025889661321200564\ \(0\)\
\-\ mandible\\:\\ 0\\.02527159154136468\ \(0\)\
\-\ bone\\:\\ 0\\.024773404617031817\ \(0\)\
\-\ periodontal\\:\\ 0\\.02402026837177466\ \(0\)\
\-\ chen\\:\\ 0\\.023412529849128144\ \(0\)\
\-\ turnover\\:\\ 0\\.02245358960762221\ \(0\)\
\-\ \\]\\:\\ 0\\.02235856501056407\ \(0\)\
\-\ \\[\\:\\ 0\\.022294047986384534\ \(0\)\
\-\ oncol\\:\\ 0\\.022060979488767597\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.021392077170560426\ \(0\)\
\-\ van\\:\\ 0\\.020358227409547628\ \(0\)\
\-\ jan\\:\\ 0\\.020143099005755723\ \(0\)\
\-\ therapy\\:\\ 0\\.019038673302005107\ \(0\)\
\-\ scintigraphic\\:\\ 0\\.018398938526540565\ \(0\)\
\-\ oral\\:\\ 0\\.01800291333178756\ \(0\)\
\-\ teeth\\:\\ 0\\.017938437398271175\ \(0\)\
\-\ mandibular\\:\\ 0\\.01763052633116779\ \(0\)\
\-\ debridement\\:\\ 0\\.01763052633116779\ \(0\)\
\-\ et\\:\\ 0\\.01748699215061141\ \(0\)\
\-\ \\:\\:\\ 0\\.016954122239859974\ \(0\)\
\-\ receiving\\:\\ 0\\.016481058043528694\ \(0\)\
\-\ long\\-term\\:\\ 0\\.01573724620581466\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.015670143515958877\ \(0\)\
\-\ necrotic\\:\\ 0\\.015574612325249888\ \(0\)\
\-\ \\,\\:\\ 0\\.014889053603450806\ \(0\)\
\-\ osteoradionecrosis\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ ibandronate\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ studying\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ bronj\\-like\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ amino\\-bisphosphonate\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ subsets\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ pai\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ chaukar\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ d\\'cruz\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ masquerading\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ oncologists\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 20071132\\.\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 340\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ c246\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 10\\.1136\\/bmj\\.c246\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 20124367\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ yamaza\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ akiyama\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ cell\\-based\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ cures\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ jaw\\-like\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ mice\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 20200952\\.\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ huizing\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ fossion\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ vermorken\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ zoledronic\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ \\:214\\-8\\.\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 20138570\\.\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ bisphosphosphonates\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ 20173017\\:\\ 0\\.014692530706610831\ \(0\)\
\-\ disease\\:\\ 0\\.013967375412157042\ \(0\)\
\-\ ak\\:\\ 0\\.013537285405677588\ \(0\)\
\-\ zhang\\:\\ 0\\.013537285405677588\ \(0\)\
\-\ shi\\:\\ 0\\.013537285405677588\ \(0\)\
\-\ nb\\:\\ 0\\.013537285405677588\ \(0\)\
\-\ endocrinol\\:\\ 0\\.013537285405677588\ \(0\)\
\-\ metab\\:\\ 0\\.013537285405677588\ \(0\)\
\-\ angle\\:\\ 0\\.013371657930777473\ \(0\)\
\-\ j\\:\\ 0\\.012865637887884127\ \(0\)\
\-\ ps\\:\\ 0\\.012861510225497315\ \(0\)\
\-\ bmj\\:\\ 0\\.012861510225497315\ \(0\)\
\-\ immunotherapy\\:\\ 0\\.012861510225497315\ \(0\)\
\-\ miner\\:\\ 0\\.012861510225497315\ \(0\)\
\-\ gupta\\:\\ 0\\.012382040104744347\ \(0\)\
\-\ s\\:\\ 0\\.012253838335572935\ \(0\)\
\-\ foreshortening\\:\\ 0\\.01201013418588733\ \(0\)\
\-\ dentist\\:\\ 0\\.01201013418588733\ \(0\)\
\-\ caution\\:\\ 0\\.01201013418588733\ \(0\)\
\-\ q\\:\\ 0\\.01201013418588733\ \(0\)\
\-\ extracted\\:\\ 0\\.011706264924564072\ \(0\)\
\-\ induce\\:\\ 0\\.011706264924564072\ \(0\)\
\-\ alterations\\:\\ 0\\.011706264924564072\ \(0\)\
\-\ model\\:\\ 0\\.011226794803811104\ \(0\)\
\-\ doi\\:\\ 0\\.011226794803811104\ \(0\)\
\-\ wang\\:\\ 0\\.011226794803811104\ \(0\)\
\-\ mt\\:\\ 0\\.011226794803811104\ \(0\)\
\-\ jb\\:\\ 0\\.011226794803811104\ \(0\)\
\-\ exposed\\:\\ 0\\.011030489744383799\ \(0\)\
\-\ permeative\\:\\ 0\\.011030489744383799\ \(0\)\
\-\ 19\\.\\:\\ 0\\.011030489744383799\ \(0\)\
\-\ eur\\:\\ 0\\.011030489744383799\ \(0\)\
\-\ res\\:\\ 0\\.011030489744383799\ \(0\)\
\-\ dl\\:\\ 0\\.011030489744383799\ \(0\)\
\-\ malignancy\\:\\ 0\\.01100696559267172\ \(0\)\
\-\ buccal\\:\\ 0\\.010854888884954087\ \(0\)\
\-\ necessitating\\:\\ 0\\.010854888884954087\ \(0\)\
\-\ kim\\:\\ 0\\.010854888884954087\ \(0\)\
\-\ \\(\\:\\ 0\\.010835425893657907\ \(0\)\
\-\ \\)\\:\\ 0\\.010703065381699576\ \(0\)\
\-\ word\\:\\ 0\\.010696038585280213\ \(0\)\
\-\ mar\\:\\ 0\\.010696038585280213\ \(0\)\
\-\ mm\\:\\ 0\\.010473983855983353\ \(0\)\
\-\ reported\\:\\ 0\\.010383582835252708\ \(0\)\
\-\ crest\\:\\ 0\\.010179113704773814\ \(0\)\
\-\ carries\\:\\ 0\\.010179113704773814\ \(0\)\
\-\ mouse\\:\\ 0\\.010179113704773814\ \(0\)\
\-\ \\;\\:\\ 0\\.010127105942262968\ \(0\)\
\-\ associated\\:\\ 0\\.01008231280953851\ \(0\)\
\-\ predisposing\\:\\ 0\\.010071549502877862\ \(0\)\
\-\ da\\:\\ 0\\.010071549502877862\ \(0\)\
\-\ colectomy\\:\\ 0\\.009970508466517137\ \(0\)\
\-\ uses\\:\\ 0\\.009875244443450558\ \(0\)\
\-\ y\\:\\ 0\\.009785132408000097\ \(0\)\
\-\ ridge\\:\\ 0\\.009699643584020846\ \(0\)\
\-\ contribute\\:\\ 0\\.009699643584020846\ \(0\)\
\-\ ad\\:\\ 0\\.009699643584020846\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.009618326643738458\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.009540793284346972\ \(0\)\
\-\ immune\\:\\ 0\\.009466707013395581\ \(0\)\
\-\ w\\:\\ 0\\.009395774322697588\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.00913885652298549\ \(0\)\
\-\ 79\\:\\ 0\\.009080370989966707\ \(0\)\
\-\ methotrexate\\:\\ 0\\.009080370989966707\ \(0\)\
\-\ le\\:\\ 0\\.009023868403840571\ \(0\)\
\-\ surgeons\\:\\ 0\\.008815263165583896\ \(0\)\
\-\ initiated\\:\\ 0\\.008766950604128474\ \(0\)\
\-\ compromise\\:\\ 0\\.008629887107066855\ \(0\)\
\-\ her\\:\\ 0\\.00856470552828312\ \(0\)\
\-\ induced\\:\\ 0\\.008544398283087604\ \(0\)\
\-\ surg\\:\\ 0\\.008503243928770318\ \(0\)\
\-\ stem\\:\\ 0\\.008463081342805216\ \(0\)\
\-\ e\\:\\ 0\\.008463081342805216\ \(0\)\
\-\ j\\.\\:\\ 0\\.008385547983413729\ \(0\)\
\-\ clin\\:\\ 0\\.008385547983413729\ \(0\)\
\-\ s\\.\\:\\ 0\\.008348093223660298\ \(0\)\
\-\ acid\\:\\ 0\\.008348093223660298\ \(0\)\
\-\ reconstruction\\:\\ 0\\.008240529021764347\ \(0\)\
\-\ changes\\:\\ 0\\.008163493254116869\ \(0\)\
\-\ mobile\\:\\ 0\\.008107124508975118\ \(0\)\
\-\ she\\:\\ 0\\.007995953804847241\ \(0\)\
\-\ a\\.\\:\\ 0\\.007983611222052248\ \(0\)\
\-\ easily\\:\\ 0\\.00786862310290733\ \(0\)\
\-\ k\\:\\ 0\\.007761058901011377\ \(0\)\
\-\ been\\:\\ 0\\.007749316298213305\ \(0\)\
\-\ excluded\\:\\ 0\\.007709772803233454\ \(0\)\
\-\ crohn\\:\\ 0\\.007611705303195232\ \(0\)\
\-\ li\\:\\ 0\\.007588064244875305\ \(0\)\
\-\ duration\\:\\ 0\\.0075417649713635125\ \(0\)\
\-\ 46\\:\\ 0\\.0075417649713635125\ \(0\)\
\-\ steroid\\:\\ 0\\.007519088884603881\ \(0\)\
\-\ dose\\:\\ 0\\.007452855003521357\ \(0\)\
\-\ 29\\:\\ 0\\.007431349328794845\ \(0\)\
\-\ these\\:\\ 0\\.007412815639859467\ \(0\)\
\-\ patients\\:\\ 0\\.007371915331220087\ \(0\)\
\-\ p\\:\\ 0\\.007307836041871974\ \(0\)\
\-\ significantly\\:\\ 0\\.007288111945793637\ \(0\)\
\-\ plate\\:\\ 0\\.00713819821802207\ \(0\)\
\-\ destruction\\:\\ 0\\.007033997623053181\ \(0\)\
\-\ majority\\:\\ 0\\.007000663178542065\ \(0\)\
\-\ complication\\:\\ 0\\.006984242684470379\ \(0\)\
\-\ uncommon\\:\\ 0\\.006967982392894772\ \(0\)\
\-\ 6\\.\\:\\ 0\\.006920132216424053\ \(0\)\
\-\ highly\\:\\ 0\\.00685839676362347\ \(0\)\
\-\ c\\:\\ 0\\.006769880388100224\ \(0\)\
\-\ 90\\:\\ 0\\.006713377801974088\ \(0\)\
\-\ 3\\:\\ 0\\.006669918422355133\ \(0\)\
\-\ 19\\:\\ 0\\.0065672018346089114\ \(0\)\
\-\ posterior\\:\\ 0\\.006565461829008162\ \(0\)\
\-\ showing\\:\\ 0\\.006554527502300213\ \(0\)\
\-\ local\\:\\ 0\\.006541948826241242\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0065407311026014\ \(0\)\
\-\ decrease\\:\\ 0\\.0065170727425467815\ \(0\)\
\-\ 11\\:\\ 0\\.0065170727425467815\ \(0\)\
\-\ were\\:\\ 0\\.006467621122299738\ \(0\)\
\-\ factors\\:\\ 0\\.006397974469243207\ \(0\)\
\-\ lytic\\:\\ 0\\.0063751430619796035\ \(0\)\
\-\ left\\:\\ 0\\.006374035128486099\ \(0\)\
\-\ medications\\:\\ 0\\.006352620196701732\ \(0\)\
\-\ started\\:\\ 0\\.006352620196701732\ \(0\)\
\-\ clinically\\:\\ 0\\.006244357036243779\ \(0\)\
\-\ pathologic\\:\\ 0\\.006233907681221119\ \(0\)\
\-\ life\\:\\ 0\\.006213203481223524\ \(0\)\
\-\ development\\:\\ 0\\.0062029470385995605\ \(0\)\
\-\ 18\\:\\ 0\\.006182621583443197\ \(0\)\
\-\ displacement\\:\\ 0\\.006103711382447865\ \(0\)\
\-\ underlying\\:\\ 0\\.006103711382447865\ \(0\)\
\-\ for\\:\\ 0\\.006075901238689292\ \(0\)\
\-\ characteristic\\:\\ 0\\.006028368987834455\ \(0\)\
\-\ drainage\\:\\ 0\\.005956285681511427\ \(0\)\
\-\ around\\:\\ 0\\.005930038419897862\ \(0\)\
\-\ references\\:\\ 0\\.005921380391769355\ \(0\)\
\-\ after\\:\\ 0\\.005893337342030675\ \(0\)\
\-\ specific\\:\\ 0\\.005887191158714183\ \(0\)\
\-\ i\\:\\ 0\\.005887191158714183\ \(0\)\
\-\ of\\:\\ 0\\.0058251900398994215\ \(0\)\
\-\ cells\\:\\ 0\\.005710744490249996\ \(0\)\
\-\ solid\\:\\ 0\\.0056805777541773\ \(0\)\
\-\ made\\:\\ 0\\.005673120620185764\ \(0\)\
\-\ use\\:\\ 0\\.005629065191738838\ \(0\)\
\-\ in\\:\\ 0\\.005618629735203399\ \(0\)\
\-\ antibiotics\\:\\ 0\\.005349527262784168\ \(0\)\
\-\ tumors\\:\\ 0\\.005349527262784168\ \(0\)\
\-\ has\\:\\ 0\\.0053489999016475935\ \(0\)\
\-\ activity\\:\\ 0\\.005343411047969231\ \(0\)\
\-\ 8\\:\\ 0\\.005325195930415581\ \(0\)\
\-\ studies\\:\\ 0\\.0053191681962986\ \(0\)\
\-\ ago\\:\\ 0\\.005301214701328748\ \(0\)\
\-\ 20\\:\\ 0\\.00512085872692836\ \(0\)\
\-\ the\\:\\ 0\\.005069140439132946\ \(0\)\
\-\ neoplasm\\:\\ 0\\.004850260959853214\ \(0\)\
\-\ swelling\\:\\ 0\\.004744684773301888\ \(0\)\
\-\ cases\\:\\ 0\\.004744684773301888\ \(0\)\
\-\ \\>\\:\\ 0\\.004731945857780941\ \(0\)\
\-\ x\\:\\ 0\\.0046984438922457955\ \(0\)\
\-\ body\\:\\ 0\\.0046254395211484745\ \(0\)\
\-\ several\\:\\ 0\\.004578488059537313\ \(0\)\
\-\ past\\:\\ 0\\.004525332453244057\ \(0\)\
\-\ medical\\:\\ 0\\.004382183000110007\ \(0\)\
\-\ age\\:\\ 0\\.004334850542573845\ \(0\)\
\-\ as\\:\\ 0\\.00430859168631376\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.004256711232742427\ \(0\)\
\-\ primary\\:\\ 0\\.004218973771492828\ \(0\)\
\-\ years\\:\\ 0\\.0041820718950308046\ \(0\)\
\-\ evaluation\\:\\ 0\\.0041370646597113465\ \(0\)\
\-\ y\\.o\\:\\ 0\\.0041106323876445\ \(0\)\
\-\ appearance\\:\\ 0\\.00407317762789107\ \(0\)\
\-\ abnormal\\:\\ 0\\.004061820400524853\ \(0\)\
\-\ region\\:\\ 0\\.004022668712065521\ \(0\)\
\-\ chronic\\:\\ 0\\.004011649388178333\ \(0\)\
\-\ include\\:\\ 0\\.003995255813383811\ \(0\)\
\-\ an\\:\\ 0\\.0039388828809491\ \(0\)\
\-\ and\\:\\ 0\\.0039001951241980667\ \(0\)\
\-\ trauma\\:\\ 0\\.0038950146362632153\ \(0\)\
\-\ at\\:\\ 0\\.003859210509438777\ \(0\)\
\-\ cell\\:\\ 0\\.0038470678526358105\ \(0\)\
\-\ fracture\\:\\ 0\\.0037551238837879647\ \(0\)\
\-\ mild\\:\\ 0\\.003750422423218562\ \(0\)\
\-\ is\\:\\ 0\\.0037486051892315045\ \(0\)\
\-\ on\\:\\ 0\\.0036194550618271404\ \(0\)\
\-\ metastatic\\:\\ 0\\.003585182339360151\ \(0\)\
\-\ surgery\\:\\ 0\\.003458331773933792\ \(0\)\
\-\ tissue\\:\\ 0\\.003375701980754323\ \(0\)\
\-\ noted\\:\\ 0\\.003375701980754323\ \(0\)\
\-\ \\%\\:\\ 0\\.003322201722243346\ \(0\)\
\-\ tumor\\:\\ 0\\.003320387169351352\ \(0\)\
\-\ a\\:\\ 0\\.003304998348488344\ \(0\)\
\-\ was\\:\\ 0\\.003294258407378956\ \(0\)\
\-\ woman\\:\\ 0\\.003289838245814844\ \(0\)\
\-\ most\\:\\ 0\\.003288058569546794\ \(0\)\
\-\ demonstrate\\:\\ 0\\.003277420235555068\ \(0\)\
\-\ well\\:\\ 0\\.003221801588281085\ \(0\)\
\-\ may\\:\\ 0\\.0031238806148302066\ \(0\)\
\-\ have\\:\\ 0\\.00308406346394182\ \(0\)\
\-\ lateral\\:\\ 0\\.0030777800760409175\ \(0\)\
\-\ 2\\:\\ 0\\.0030668408275175774\ \(0\)\
\-\ to\\:\\ 0\\.002847120722953242\ \(0\)\
\-\ also\\:\\ 0\\.0028076993227835858\ \(0\)\
\-\ which\\:\\ 0\\.0026585743120709146\ \(0\)\
\-\ that\\:\\ 0\\.0024599678809313725\ \(0\)\
\-\ by\\:\\ 0\\.0023714515054081248\ \(0\)\
\-\ be\\:\\ 0\\.0021962612055732153\ \(0\)\
\-\ there\\:\\ 0\\.002119525927441648\ \(0\)\
\-\ \\.\\:\\ 0\\.0020708062723451995\ \(0\)\
\-\ history\\:\\ 0\\.0019670242295118058\ \(0\)\
\-\ are\\:\\ 0\\.001941456454216003\ \(0\)\
\-\ patient\\:\\ 0\\.0014276532181939801\ \(0\)\
\-\ with\\:\\ 0\\.000780027840599265\ \(0\)\
